Digoxin

Progress in Cardiovascular Diseases

Volumn 44, Issue 4, 2002, Pages 251-266

  Eichhorn, Eric J ^a,b   Gheorghiade, Mihai ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ABDOMINAL PAIN; ANOREXIA; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INOTROPISM; INTESTINE ISCHEMIA; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NEUROTOXICITY; REVIEW; SURVIVAL; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; VISUAL IMPAIRMENT; VOMITING;

EID: 0036224231     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2002.31591     Document Type: Article

References (96)

1. An account of the foxglove and some of its medical uses, with practical remarks on dropsy, and other diseases
2. Digoxin
3. Clinical experience in protecting the failing heart
4. Digitalis effects in chronic cardiac cases with regular rhythm in contrast to auricular fibrillation
5. Digitalis and diuretics in heart failure with regular rhythm, with special reference to importance of etiologic classification of heart disease
6. Studies on cardiodynamic action of drugs III. The mechanism of cardiac stimulation by digitalis and g-strophanthin
7. The influence of digitalis glycosides on the force of contraction of mammalian cardiac muscle
8. The effects of the cardiac glycosides upon the dynamics of the circulation in congestive heart failure: I. Ouabain
9. Action of digitalis upon the non-failing heart: A critical review
10. Long-term digitalis therapy improves left ventricular function in heart failure
11. Are contraction and relaxation coupled in patients with and without congestive heart failure?
12. Is digoxin really important in compensated heart failure?
13. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease. A randomized placebo-controlled crossover trial
14. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure
15. Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm
16. Is maintenance digoxin necessary in patients with sinus rhythm?
17. Discontinuation of maintenance digoxin therapy in general practice
18. Digitalis glycosides: Mechanisms and manifestations of toxicity
19. Digoxin intoxication: The relationship of clinical presentation to serum digoxin concentration
20. Digitalis intoxication: A prospective clinical study with serum level correlations
21. Pharmacotherapy for systolic dysfunction: A review of randomized clinical trials
22. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure
23. A controlled trial of digoxin in congestive heart failure
24. Long-term effects of digoxin and diuretics in congestive heart failure: Results of a placebo-controlled randomized double blind study
25. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure
26. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: Results of the Dutch Ibopamine Multicenter trial (DIMT)
27. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors
28. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate congestive heart failure. Results of the PROVED trial
29. Review of randomized trials of digoxin therapy in patients with chronic heart failure
30. Heart failure in outpatients: A randomized trial of digoxin versus placebo
31. The effect of digoxin on mortality and morbidity in patients with heart failure
32. Stimulation and inhibition of the Na+, K+ pump by cardiac glycosides
33. Comparison of effects of dobutamine and ouabain on left ventricular contraction and relaxation in closed-chest dogs
34. The chronic effects of long-term digoxin administration on Na+/K(+)-ATPase activity in rat tissues
35. Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function and energetics in failing human myocardium
36. Effects of digitalis on the normal and the failing heart
37. Studies on digitalis: IX. Effects of ouabain on the non-failing heart
38. Studies on digitalis: IX. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients with heart failure
39. On the difference between the heart's output and its contractile state
40. Extracardiac and coronary vascular effects of digitalis
41. Studies on digitalis: I. Direct effects on peripheral vascular resistance
42. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?
43. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors
44. Enalapril versus digoxin in patients with congestive heart failure: A multicenter study
45. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure
46. Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with congestive heart failure
47. No adaptation to digitalization as evaluated by digitalis receptor (Na, K-ATPase) quantification in explanted hearts from donors without heart disease and from digitalized recipients with end-stage heart failure
48. No upregulation of digitalis glycoside receptor (Na, K-ATPase) concentration in human heart left ventricle samples obtained at necropsy after long term digitalisation
49. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators
50. Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure
51. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
52. Digoxin: A neurohormonal modulator in heart failure?
53. Carotid sinus baroreceptor sensitivity in experimental heart failure
54. Effect of digitalis on carotid sinus baroreceptor activity
55. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure
56. Heart rate variability in patients with mild to moderate heart failure - Effects on neurohormonal modulation by digoxin and ibopamine
57. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: A hemodynamic-hormonal study
58. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure
59. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings
60. Role of the adrenergic nerve terminal in the digitalis-induced cardiac toxicity: A study of the effects of pharmacological and surgical denervation
61. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain
62. Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure
63. Effect of a digitalis drug on ventricular premature beats
64. Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock
65. Superiority of "triple" drug therapy in heart failure: Insights from the PROVED and RADIANCE Trials
66. Digoxin for chronic heart failure: A review of the randomized controlled trials with special attention to the PROVED and RADIANCE trials
67. Clinical pharmacology of digoxin
68. The effect of different digoxin doses on subjective symptoms and physical working capacity in patients with atrial fibrillation
69. Optimal heart rate control for patients with chronic atrial fibrillation: Are pharmacologic choices truly changing?
70. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial
71. Standards of laboratory practice: Cardiac drug monitoring
72. The evolving pattern of digoxin intoxication: Observations at a large urban hospital from 1980 to 1988
73. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: Final report of a multicenter study
74. Digitalis Investigation Group (DIG) trial: A stimulus for further research
75. Antiarrhythmic drug use and high serum levels of digoxin are independent adverse prognostic factors in patients with chronic heart failure
76. +)-ATPase and cardiac glycoside binding
77. Ouabain-induced tachyarrythmias and cell damage in isolated perfused guinea-pig hearts: Protection by propranolol
78. Facilitation of lethal ventricular arrhythmias by therapeutic digoxin in conscious postinfarction dogs
79. Reduction in digitalis-associated postinfarction mortality with nadolol in conscious dogs
80. Are low serum levels of digoxin effective in chronic heart failure? Evidence challenging the accepted guidelines for a therapeutic serum level of the drug
81. Patients with mild heart failure worsened during withdrawal from digoxin therapy
82. Chronic heart failure in the United States: A manifestation of coronary arterydisease
83. Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure
84. Digoxin and mortality in survivors of acute myocardial infraction: Observation in patients at low and intermediate risk
85. The effects of digoxin withdrawal in patients with stable heart failure due to coronary artery disease compared to primary cardiomyopathy: Insights from PROVED and RADIANCE studies
86. Effect of acute magnesium administration in the frequency of ventricular arrhythmias in patients with heart failure
87. Dose-related cardiovascular effects of spironolatone
88. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension
89. Digoxin enhances the pressor response to aldosterone administration in conscious sheep
90. Angiotensin-II inhibits Na+/K+ pump in rat adrenal glomerulosa cells: Possible contribution to stimulation of aldosterone production
91. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
92. Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity
93. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade
94. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure
95. Heart failure in patients with preserved left ventricular systolic function: Do digitalis glycosides have a role?
96. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure